Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas

NCT05910827 is registered in ClinicalTrials.gov with Hummingbird Bioscience as lead sponsor.

NCT NCT05910827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05910827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas
Lead sponsor
Hummingbird Bioscience
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 5, 2024
Completion date
December 31, 2027
Enrollment
398 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cutaneous squamous cell carcinoma, advanced esophageal squamous cell carcinoma, advanced head and neck squamous cell carcinoma, advanced or metastatic squamous non-small cell lung cancer, cervical squamous cell carcinoma, nasopharyngeal cancinoma (npc), squamous cell carcinoma